Warning letter
IVAX Pharmaceuticals Inc.: warning letter of May 14, 2001
FDA warning letter UCM069672 · New Jersey District Office
Key facts
| Reference number | UCM069672 |
|---|---|
| Company | IVAX Pharmaceuticals Inc. |
| Subject | CGMP for Finished Pharmaceutical/Adulterated |
| Issue date | May 14, 2001 |
| Posted date | May 14, 2001 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| Country | 3 |
| Inspection city | Northvale |
| Inspection ZIP | 07647-2403 |
| Inspection start date | Feb 28, 2001 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: